ACE2 and COVID-19: Furthermore, accumulating evidence suggests that COVID-19 is more prevalent among individuals suffering from T2DM and hypertension (6–8), with studies showing that treatment of these patients with angiotensin-converting enzyme 2 (ACE2)-increasing drugs could lead to a severe outcome (9).